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Abstract
Introduction: During the past decade, the incidence of Candida infections in hospitalized patients has increased,
with fluconazole being the most commonly prescribed systemic antifungal agent for these infections. However, the
2009 Infectious Diseases Society of America (IDSA) candidiasis guidelines recommend an echinocandin for the
treatment of candidemia/invasive candidiasis in patients who are considered to be “moderately severe or severely”
ill. To validate these guidelines, clinical trial data were reviewed.
Methods: A secondary analysis of data from a previously published prospective, randomized, double-blind clinical
trial was performed; it compared anidulafungin with fluconazole for the treatment of invasive candidiasis and
candidemia. Patients with critical illness were identified at study entry by using the following criteria: Acute
Physiology and Chronic Health Evaluation (APACHE) II score of ≥ 15, evidence of severe sepsis (sepsis and one or
more end-organ dysfunctions) present, and/or patient was in intensive care. Global response rates were compared
at the end of intravenous study treatment (the primary end point of the original study) and all-cause mortality at
14 and 28 days from study entry in this group.
Results: The patients (163 (66.5%) of 245) fulfilled at least one criterion for critical illness (anidulafungin, n = 89;
fluconazole, n = 74). No significant differences were found in baseline characteristics between the two treatment
groups. The global response rate was 70.8% for anidulafungin and 54.1% for fluconazole (P = 0.03; 95% confidence
interval (CI): 2.0 to 31.5); all-cause mortality was 10.1% versus 20.3% at 14 days (P = 0.08; 95% CI, -0.9 to 21.3) and
was 20.2% versus 24.3% at 28 days (P = 0.57; 95% CI, -8.8 to 17.0) for anidulafungin and fluconazole, respectively.
Conclusions: In this post hoc analysis, anidulafungin was more effective than fluconazole for treatment of severely
ill patients with candidemia, thus supporting the 2009 IDSA guidelines.
Trial registration: Clinicaltrials.gov NCT00058682.
Introduction
The incidence of Candida infections in hospitalized
patients has increased over the past decade [1-6]. Can-
dida spp. are now the third most frequent cause of
nosocomial bloodstream infections in the intensive care
unit (ICU), accounting for up to 10% to 15% of all septi-
cemia cases in this setting [1,4-6]. In the United States,
the incidence of Candida bloodstream infections in sur-
gical ICUs was reported to be 9.82 per 1,000 admissions
[7], and, in a large international survey, the prevalence
was 6.9 per 1,000 ICU admissions [8]. Candida blood-
stream infections in the ICU are commonly associated
with high mortality [1,6,9-11], and a European study
showed mortality in ICU patients with candidemia to be
significantly higher than that in the overall population
of hospitalized patients [12]. Worldwide, C. albicans
remains the most common Candida spp. responsible for
candidemia, whereas non-albicans spp. compose 40%;
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causative Candida spp. have been noted [13-16].
Fluconazole remains the most commonly prescribed
systemic antifungal agent for treatment of candidemia
and other forms of invasive candidiasis [8,10,17]. How-
ever, the 2009 Infectious Diseases Society of America
(IDSA) treatment guidelines favor an echinocandin (ani-
dulafungin, caspofungin, or micafungin) as initial ther-
apy for candidemia in patients with “moderately severe
to severe” illness, with fluconazole reserved for patients
who are less severely ill [18]. The echinocandins are
highly active against a broad spectrum of Candida spp.
(anidulafungin minimum inhibitory concentration (MIC)
50/MIC90 0.06/2 μg/ml; caspofungin MIC50/MIC90, 0.03/
0.25 μg/ml, and micafungin MIC50/MIC90 0.015/1 μg/
ml), including C. glabrata and C. krusei,a g a i n s tw h i c h
the azole antifungal agents are known to have less activ-
ity [19]. In prospective, randomized clinical trials, caspo-
fungin has been demonstrated to be at least as effective
as amphotericin B [20], and micafungin was shown to
be as effective as liposomal amphotericin B [21] and cas-
pofungin [22]. Only one study to date has compared an
echinocandin with fluconazole for the treatment of can-
didemia [23]. In that prospective, randomized, double-
blind study, global success at end of intravenous treat-
ment was 75.6% in the anidulafungin group, compared
with 60.2% in the fluconazole group (95% confidence
interval (CI) 3.9 to 27.0) [23]. The results were similar
for other efficacy end points. Based on a review of the
distribution of baseline Acute Physiology and Chronic
Health Evaluation (APACHE) II scores in this study
[23], we suspected that a substantial proportion of
patients would be considered severely ill at study entry.
We saw this as an opportunity to compare outcomes in
these patients, allowing us to validate the 2009 IDSA
candidemia treatment guidelines.
Materials and methods
I nt h ep r e v i o u s l yp u b l i s h e ds t u d y ,2 4 5a d u l tp a t i e n t s
with culture-confirmed candidemia were randomly
assigned to receive initial study treatment with either
intravenous (IV) anidulafungin or fluconazole. Patients
were administered IV anidulafungin (200 mg on day 1,
and then 100 mg daily) or IV fluconazole (800 mg on
day 1, and then 400 mg daily) for ≥ 10 days. Therapy
with IV study drug was optionally followed by oral flu-
conazole if certain predefined conditions were met. The
study protocol was approved by the institutional review
board at each of the participating centers, and all
patients, or their legal representatives, provided written
informed consent before enrollment. The trial was regis-
tered on Clinicaltrials.gov (NCT00058682). Complete
details on study design and results were published else-
where [23].
Patients in this study were considered to be severely ill
if they met any of the following criteria at study entry:
APACHE II score ≥ 15 (which was above the median
APACHE II score of patients in the primary study [23]
and is associated with a mortality of 20% or greater in
patients with severe sepsis [24]); requirement for inten-
sive care; or evidence of severe sepsis present. The origi-
nal study required that patients have a diagnosis of
candidemia and meet at least two of the criteria for sys-
temic inflammatory response syndrome (SIRS) [25].
Consensus definitions for end-organ dysfunction were
developed based on the clinical and laboratory data col-
lected during the study: cardiovascular dysfunction was
defined as a need for a vasopressor agent within 24
hours of study entry; renal dysfunction was defined as a
calculated creatinine clearance < 30 ml/min [26] or
need for dialysis at study entry; respiratory dysfunction
was defined as a requirement for mechanical ventilation;
hepatic dysfunction was defined as total bilirubin level
greater than twice the upper limit of normal (ULN) or
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), or alkaline phosphatase greater than 5
times ULN; multiple organ dysfunction was defined as
the presence of more than one single-organ dysfunction.
The primary analysis was a comparison of the investi-
gator-assessed global (that is, combined clinical and
microbiologic) response at the end of IV study treat-
ment (referred to hereafter as end of treatment) with
either anidulafungin or fluconazole. Secondary analyses
included comparison of global response in each of the
three subpopulations: (a) patients with APACHE II
score ≥ 15; (b) patients in an ICU; and (c) patients with
severe sepsis. To identify any potential imbalances
between treatment groups, baseline demographic and
clinical characteristics were compared by using the
Fisher Exact test or t test, as appropriate. The limited
sample size did not provide sufficient power to adjust
for possible confounders or multiple comparisons within
groups. All-cause mortality was compared at 14 days
(the median duration of treatment with anidulafungin)
and at 28 days, by using the Fisher Exact test. Survival
duration at 14 and 28 days was also compared by using
Kaplan-Meier analysis and the log-rank test.
Results
Of the 245 patients, 163 (66.5%) fulfilled at least one of
the criteria for critical illness: 89 received anidulafungin,
and 74 received fluconazole. We found no significant
differences in baseline characteristics between the two
treatment groups (Table 1). In patients with critical ill-
ness overall, the global response rate was 70.8% for ani-
dulafungin and 54.1% for fluconazole (P = 0.03; 95% CI,
2.0 to 31.5); all-cause mortality at 14 days was 10.1%
versus 20.3% (P = 0.08 by the Fisher Exact test; 95% CI,
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(P = 0.57 by the Fisher Exact test; 95% CI, -8.8 to 17.0) for
anidulafungin and fluconazole, respectively (Table 2 and
Figure 1). The Kaplan-Meier comparison of survival at day
14 is presented in Figure 2 (P = 0.07 by log-rank test).
APACHE II score ≥ 15
Of the original 245 patients, 113 (46.1%) had an
APACHE II score ≥ 15 at study entry: 63 were treated
with anidulafungin, and 50 with fluconazole. In this
group, global response at the end of treatment was sig-
nificantly higher with anidulafungin than with flucona-
zole (68.3% versus 46.0%; P < 0.05; 95% CI, 4.3 to 40.2)
(Table 2 and Figure 1). All-cause mortality at 14 days
was 14.3% for anidulafungin and 28.0% for fluconazole,
with a difference of 13.7 percentage points (95% CI, -1.4
to 28.9; P = 0.10 by the Fisher Exact test). All-cause
mortality at 28 days was 27.0% for anidulafungin and
34.0% for fluconazole, with a difference of 7.0 percen-
tage points (95% CI, -10.0 to 24.1; P = 0.54 by the Fisher
Exact test). No statistically significant differences were
found in the comparisons of Kaplan-Meier estimates of
survival at day 14 (P =0 . 0 7b yl o g - r a n kt e s t )o rd a y2 8
(P = 0.42 by log-rank test).
Severe sepsis
Of the original 245 patients, 118 (48.2%) met the criteria
for severe sepsis (SIRS with end-organ dysfunction) at
study entry: 62 were treated with anidulafungin, and 56
with fluconazole. Global response at end of treatment
(Table 2 Figure 1) was 67.7% for anidulafungin and
51.8% for fluconazole (P = 0.092; 95% CI, -1.6 to 33.5).
All-cause mortality at 14 days was 12.9% for anidulafun-
gin and 19.6% for fluconazole, with a difference of 6.7
percentage points (95% CI, -6.6 to 20.1; P =0 . 4 5b y
Fisher Exact test); all-cause mortality at 28 days was
25.8% for anidulafungin and 25.0% for fluconazole, with
a difference of -0.8 percentage points (95% CI, -17.0 to
14.9; P = 0.93 by Fisher Exact test). No statistically sig-
nificant differences were noted in the comparisons of
Kaplan-Meier estimates of survival at day 14 (P =0 . 3 3
by log-rank test) or day 28 (P = 0.98 by log-rank test).
Of the 118 patients with severe sepsis, 44 patients had
respiratory dysfunction, 69 patients had renal dysfunc-
tion, 34 patients had hepatic dysfunction, 33 patients had
cardiovascular dysfunction, and 45 had multiple end-
organ dysfunction. The global responses in each of these
subpopulations are presented in Table 2 and Figure 1.
For patients with multiple end-organ dysfunction, global
response at end of treatment (Table 2 and Figure 1) was
76.2% for anidulafungin and 29.2% for fluconazole (P <
0.05; 95% CI, 21.3 to 72.8). In this subpopulation, all-
cause mortality at 14 days was 19.0% for anidulafungin
and 29.2% for fluconazole, with a difference of 10.1 per-
centage points (95% CI, -15.0 to 34.9; P =0 . 5 0b yF i s h e r
Exact test), and all-cause mortality at 28 days was 38.1%
for anidulafungin and 33.3% for fluconazole, with a dif-
ference of -4.8 percentage points (95% CI, -33.0 to 23.3;
P = 0.77 by Fisher Exact test). Again, no statistically sig-
nificant differences were seen in the comparisons of
Kaplan-Meier estimates of survival at day 14 (P =0 . 4 5b y
log-rank test) or day 28 (P = 0.85 by log-rank test).
ICU patients
Hospital records for 166 of the 245 study patients were
reviewed to identify patients in an ICU at study entry.
Of the 166 patients, 63 were found to be in an ICU at
study entry, and of these, 35 patients received anidula-
fungin and 28 received fluconazole. Global response at
end of treatment (Table 2 and Figure 1) was 68.6% for
anidulafungin and 46.4% for fluconazole (P = 0.122; 95%
Table 1 Baseline demographic and clinical characteristics
in severely ill patients
Anidulafungin
(n = 89)
Fluconazole
(n = 74)
Age (years), mean (SD) 60.2 (16.4) 62.2 (16.4)
APACHE II score, mean (SD) 18.0 (7.0) 17.3 (6.8)
Gender, n (%)
Male 45 (50.6) 41 (55.4)
Female 44 (49.4) 33 (44.6)
Race, n (%)
White 65 (73.0) 59 (79.7)
Black 19 (21.3) 9 (12.2)
Other 5 (5.6) 6 (8.1)
Absolute neutrophil count, n (%)
≤ 500 3 (3.4) 4 (5.4)
> 500 86 (96.6) 70 (94.6)
Risk factors for candidemia, n (%)
Central venous catheter 71 (79.8) 58 (78.4)
Broad-spectrum antibiotics 65 (73.0) 53 (71.6)
Recent surgery 37 (41.6) 34 (45.9)
Recent hyperalimentation (TPN) 25 (28.1) 16 (21.6)
Malignancy 23 (25.8) 16 (21.6)
Immunosuppressive therapy 14 (15.7) 19 (25.7)
Transplant 5 (5.6) 4 (5.4)
Source of isolates, n (%)
Candidemia 85 (95.5) 69 (93.2)
Intra-abdominal infection 4 (4.5) 5 (6.8)
Candida spp., n (%)
Single isolate 81 (91.0) 69 (93.2)
C. albicans 45 (50.6) 43 (58.1)
C. glabrata 15 (16.9) 14 (18.9)
C. parapsilosis 10 (11.2) 4 (5.4)
C. tropicalis 9 (10.1) 6 (8.1)
Mixed 8 (9.0) 5 (6.8)
APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard
deviation; TPN, total parenteral nutrition.
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for anidulafungin and 21.4% for fluconazole (95% CI,
-4.9 to 30.7; P = 0.17 by Fisher Exact test). All-cause
mortality at 28 days was 17.1% for anidulafungin and
28.6% for fluconazole (95% CI, -9.4 to 32.3; P =0 . 3 6b y
Fisher Exact test). No statistically significant differences
were found in the comparisons of Kaplan-Meier esti-
mates of survival at day 14 (P = 0.16 by log-rank test)
or day 28 (P = 0.27 by log-rank test).
Safety
The number of treatment-related adverse events was
similar in the two treatment arms: 44 treatment-related
adverse events were reported in 22 (23.7%) of 93
patients receiving anidulafungin, and 40 treatment-
related adverse events were reported in 21 (27.3%) of 77
patients receiving fluconazole. All-causality adverse
events leading to discontinuation of the study drug
occurred in 13 (14%) of 93 patients receiving anidula-
fungin and in 18 (23.4%) of 77 patients receiving fluco-
nazole (P = 0.16). The majority of these treatment-
Table 2 Global response at end of treatment among severely ill patients and the various subpopulations
Patient group Global response at end of treatment
Anidulafungin Fluconazole P value Absolute difference (95% CI)
n (%)
Moderate to severe illness Success 63/89 (70.8) 40/74 (54.1) 0.034 16.7% (2.0, 31.5)
Failure 26/89 (29.2) 34/74 (45.9)
APACHE II ≥ 15 Success 43/63 (68.3) 23/50 (46.0) 0.022 22.3% (4.3, 40.2)
Failure 20/63 (31.7) 27/50 (54.0)
Severe sepsis with ≥ 1 organ dysfunction Success 42/62 (67.7) 29/56 (51.8) 0.092 16.0% (-1.6, 33.5)
Failure 20/62 (32.3) 27/56 (48.2)
Respiratory dysfunction Success 16/22 (72.7) 7/22 (31.8) 0.015 40.9% (14.0, 67.8)
Failure 6/22 (27.3) 15/22 (68.2)
Renal dysfunction Success 26/36 (72.2) 18/33 (54.5) 0.142 17.7% (-4.7, 40.1)
Failure 10/36 (27.8) 15/33 (45.5)
Hepatic dysfunction Success 13/18 (72.2) 7/16 (43.8) 0.163 28.5% (-3.4, 60.4)
Failure 5/18 (27.8) 9/16 (56.3)
Cardiovascular dysfunction Success 6/13 (46.2) 8/20 (40.0) 1.000 6.2% (-28, 40.7)
Failure 7/13 (53.8) 12/20 (60.0)
Severe sepsis with multiple organ dysfunction Success 16/21 (76.2) 7/24 (29.2) 0.003 47.0% (21.3, 72.8)
Failure 5/21 (23.8) 17/24 (70.8)
Treatment in ICU Success 24/35 (68.6) 13/28 (46.4) 0.122 22.1% (-1.9, 46.2)
Failure 11/35 (31.4) 15/28 (53.6)
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worsening disease rather than adverse events related to
medication toxicity.
Discussion
The 2009 IDSA candidemia treatment guidelines recom-
mend initial treatment with an echinocandin in patients
with “moderately severe to severe” illness [18]. To vali-
date these guidelines for the treatment of candidemia,
we identified a group of patients with critical illness at
study entry in a prospective, randomized clinical trial
that compared anidulafungin with fluconazole [23]. In
this group, global response at end of treatment was sig-
nificantly higher with anidulafungin than with
fluconazole.
We believe that this global-response observation sup-
ports the IDSA candidemia guidelines, as well as current
European guidelines that recommend an echinocandin
for treatment of candidemia in hemodynamically
unstable ICU patients [27]. Three recent reports, how-
ever, were unable to confirm the advantage of an echi-
nocandin over other systemic antifungal agents for the
treatment of candidemia in ICU patients. Two post hoc
subgroup analyses of data collected in prospective ran-
domized studies reported similar clinical responses and
all-cause mortality in ICU patients receiving initial treat-
ment with an echinocandin (micafungin or caspofungin)
when compared with amphotericin B-based comparators
[28,29]. Similarly, a post hoc analysis of patients with
candidemia requiring mechanical ventilation failed to
demonstrate a survival advantage for an echinocandin
compared with fluconazole, even after adjusting for non-
treatment factors [30]. In our analysis, similar patients
with candidemia and respiratory failure who were trea-
ted with anidulafungin had better global responses at
the end of treatment compared with those with flucona-
zole, but no significant difference in survival was found.
In contrast to other studies, we did not limit our analy-
s i st oI C Up a t i e n t s .T ob em o r ec o n s i s t e n tw i t ht h e
IDSA guidelines, we identified patients who were con-
sidered to be “moderately severe to severely ill” and
included patients outside of an ICU setting.
The recent IDSA clinical practice guidelines suggest
that more severely ill patients with candidemia should
receive echinocandins as first-line therapy [18]; however,
they do not provide a definition for “moderately severe
to severe” illness. To test these recommendations, we
had to create a clinically valid definition for this patient
population. We first attempted to identify patients who
were likely to have been severely ill because they were
in an ICU at study entry. However, this information was
not collected in the casebook, and hospital medical
records were available for review for only two thirds of
the study population. In addition, criteria for ICU
admission were potentially different across study sites.
We then considered all patients with a baseline
APACHE II score ≥ 15 at study entry to be severely ill,
because this score is associated with a mortality of 20%
or greater in septic patients [24]. However, these
APACHE II scores were calculated at study entry, and
not necessarily at the time of ICU admission, where
these scores have been validated. We then identified all
patients with sepsis and evidence of organ dysfunction
at study entry because these patients would also be con-
sidered to be severely ill. To accomplish this, we gener-
ated and applied consensus definitions for severe sepsis
with respiratory, renal, hepatic, and/or cardiovascular
dysfunction based on the information collected during
the study. The data required to categorize other types of
end-organ (for example, central nervous system) dys-
function, or those with septic shock, however, were not
collected in a consistent manner in the study case-
report form.
We considered patients who met any of these three
criteria to be severely ill for the purpose of this analysis.
This strategy has the advantage of allowing us to iden-
tify these patients independent of hospital ward location,
as well as APACHE II scores at study entry. However,
prospective studies using more-formal definitions for
severely ill patients with candidemia should be consid-
ered. In addition, step-down therapy to fluconazole
should be evaluated for patients who have improved
clinically after initial therapy with an echinocandin and
who are infected with an organism that is likely to be
fluconazole susceptible, in line with IDSA guidelines
[18]. As reported by Reboli et al. [23], the majority of
pathogens isolated in this study, including C. glabrata
isolates, were susceptible to fluconazole. Of note, several
critically ill patients with C. parapsilosis infection had a
satisfactory response to anidulafungin.
Our study has important limitations. It is a post hoc
analysis of the prospective, randomized, double-blind,
clinical trial that compared anidulafungin with flucona-
zole for the treatment of candidemia [23]. The defini-
tions used to classify patients as severely ill relied on
data obtained from case-report forms and from a post
hoc chart review encompassing the majority of rando-
mized patients. Additionally, a substantial overlap
existed between these definitions; therefore, some
patients were included in more than one of the resulting
three groups. Although a numerically greater global
response was noted with anidulafungin versus flucona-
zole in essentially all subsets of severely ill patients, clas-
sification of patients into three groups resulted in
relatively small sample sizes, and for several of these
groups, the difference in global response rates did not
approach statistical significance. In addition, subdivision
into small sample sizes meant that this analysis was
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the two treatment groups, and no statistically significant
differences were observed. In the anidulafungin and flu-
conazole comparative trial [23], a trend toward
improved survival was seen in patients receiving anidu-
lafungin (P = 0.10 when comparing Kaplan-Meier esti-
mates of survival).
In summary, in our analysis of severely ill patients with
candidemia, anidulafungin was associated with improved
global response at end of study treatment compared with
fluconazole. Although derived from a post hoc analysis of
clinical trial data, these observations support the 2009
IDSA treatment guidelines, which recommend an echi-
nocandin for primary treatment of moderately severe to
severely ill patients with candidemia. Additional studies
should be conducted the better to define the critical care
patient population(s) that would most benefit from initial
treatment with an echinocandin.
Key messages
￿ Fluconazole is the most common systemic antifungal
agent prescribed for treatment of candidemia and
invasive candidiasis; however, the 2009 Infectious Dis-
eases Society of America (IDSA) treatment guidelines
favor an echinocandin as initial therapy for candidemia
in patients with moderately severe to severe illness.
￿ This retrospective review of data from the prospec-
tive, randomized, double-blind clinical trial demon-
strated that anidulafungin is more effective than
fluconazole for treatment of severely ill patients with
candidemia, thus supporting the 2009 IDSA guidelines.
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